Document Detail

Statins for primary prevention in type 2 diabetes.
MedLine Citation:
PMID:  16903486     Owner:  NLM     Status:  MEDLINE    
At least 1 in 40 people in the UK have type 2 diabetes mellitus, and the prevalence is increasing. Such people are more likely than others to develop, and to die from, cardiovascular disease. Statin therapy helps to prevent cardiovascular disease events among patients at increased risk, with or without diabetes, and is standard treatment for patients needing secondary prevention. Here we discuss whether statins should be used routinely for primary prevention of cardiovascular disease in patients with type 2 diabetes irrespective of other risk factors.
Related Documents :
17323586 - Olmesartan medoxomil: current status of its use in monotherapy.
15816266 - Assessment of risk for type 2 diabetes mellitus in a caribbean population with high dia...
21078616 - The hemostatic system in patients with type 2 diabetes with and without cardiovascular ...
14692296 - Nutrition interventions for prevention of type 2 diabetes and the metabolic syndrome.
25166296 - The evaluation of clinical and cost outcomes associated with earlier initiation of insu...
8148186 - Cotside plasma rather than whole blood estimates of blood glucose in the newborn.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Drug and therapeutics bulletin     Volume:  44     ISSN:  0012-6543     ISO Abbreviation:  Drug Ther Bull     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-14     Completed Date:  2007-01-11     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0112037     Medline TA:  Drug Ther Bull     Country:  England    
Other Details:
Languages:  eng     Pagination:  57-60     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Diabetes Mellitus, Type 2 / complications*
Diabetic Angiopathies / prevention & control*
Double-Blind Method
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of S6-strain Mycoplasma gallisepticum inoculation at ten, twenty-two, or forty-five weeks of...
Next Document:  Is minocycline overused in acne?